Celldex Therapeutics, Inc.
NASDAQ:CLDXBiotechnology
+$0.16 today
- Market cap
- $2.16B
- Beta
- 0.93
- P/E (TTM)
- -7.8
- EPS (TTM)
- -$4.26
Volume 0.68M
Average 0.94M
CLDX Other Income / Expenses
Net non-operating gains and losses, such as investment results, currency effects, and one-off items.
Celldex Therapeutics, Inc.NASDAQ: CLDX
Other Income / Expenses · Q3 FY2026 · quarter ended Sep 2026
Other income / expenses growth accelerates
Q3 FY2026 other income / expenses of $6.69M rose 1.8% year over year, ahead of the -19.9% change in trailing-twelve-month other income / expenses. Sequentially, it fell 6.0% from the prior quarter. Over 3 fiscal years it compounded at +114.2% a year.
Context
- Other income / expenses amounted to 1906.7% of revenue in FY2025, up 1376.5 pp from a year earlier.
- Other income / expenses increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +1.8% holds above the trailing-twelve-month pace of -19.9%.
Sources:Income StatementText generated from reported figures; not investment advice.
Other Income / Expenses history
USD · from the income statement
- Latest · FY2025
- 28.6M USD
- Year-over-year change
- -23.1%
- 4-year CAGR
- +174.3%
| Period | Period end | Other Income / Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 28.6M | -23.1% |
| FY2024 | 2024-12-31 | 37.22M | +183.8% |
| FY2023 | 2023-12-31 | 13.11M | +350.8% |
| FY2022 | 2022-12-31 | 2.91M | +476.0% |
| FY2021 | 2021-12-31 | 505K | — |
Other Income / Expenses vs competitors
How CLDX compares with its peers on the latest reported figures
- CLDX's LTM Sep 2026 other income / expenses of $25.39M is the 4th highest of the 10 companies compared; the peer median is $18.04M.
- Its year-over-year change of -19.9% is the 7th highest of 9, against a peer median of +6.1%.
- Other income / expenses amounts to 22670.5% of revenue for CLDX, versus a peer median of 29.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $55.23M | +206.4% | +46.5% | 52.6% | |
| LTM Mar 2026 | $54.3M | +157.6% | — | 43.8% | |
| LTM Jun 2026 | $34M | +6.3% | +33.1% | 29.1% | |
| LTM Sep 2026 | $25.39M | -19.9% | +114.2% | 22670.5% | |
| LTM Aug 2026 | $18.56M | -20.1% | +84.3% | 2.6% | |
| LTM Sep 2026 | $18.04M | +57.2% | +600.5% | — | |
| LTM Mar 2026 | $7M | +6.0% | +37.7% | — | |
| LTM Jun 2024 | $4.52M | — | -7.1% | 554.5% | |
| LTM Mar 2026 | $4.18M | -19.6% | +32.8% | 5.8% | |
| LTM Mar 2026 | -$7.37M | -116.5% | — | 4.7% | |
VRXAVeraxa Biotech Holding AG | — | — | — | — | — |
| Peer median (excluding CLDX) | $18.04M | +6.1% | +37.7% | 29.1% | |
Competitors are the stored peer set for CLDX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 4.65M | 2.36M | 6.88M | 7.02M | 1.5M |
| Cost of Revenue | 53.31M | 82.26M | 118.01M | 163.55M | 0 |
| Gross Profit | (48.66M) | (79.9M) | (111.13M) | (156.53M) | 1.5M |
| Gross Margin | -1046.2% | -3389.9% | -1614.5% | -2229.8% | 100.0% |
| Research & Development | 56.81M | 82.26M | 118.01M | 163.55M | 245.1M |
| Selling, General & Admin | 20.49M | 27.2M | 30.91M | 38.55M | 43.8M |
| Operating Expenses | 22.58M | 35.33M | 43.41M | 38.55M | 288.9M |
| Depreciation & Amortization | 3.07M | 2.9M | 3.01M | 3.18M | 3.38M |
| EBITDA | (66.08M) | (104.2M) | (139.03M) | (154.69M) | (255.42M) |
| EBITDA Margin | -1420.8% | -4420.9% | -2020.0% | -2203.5% | -17028.0% |
| Operating Income | (71.24M) | (115.23M) | (154.54M) | (195.08M) | (287.4M) |
| Operating Margin | -1531.8% | -4889.0% | -2245.3% | -2778.9% | -19160.0% |
| Interest Income | 505K | 2.91M | 13.11M | 37.22M | 28.61M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 505K | 2.91M | 13.11M | 37.22M | 28.6M |
| Income Before Tax | (70.74M) | (112.33M) | (141.43M) | (157.86M) | (258.8M) |
| Pre-Tax Margin | -1520.9% | -4765.6% | -2054.8% | -2248.8% | -17253.3% |
| Income Tax Expense | (227K) | 0 | 0 | 0 | 0 |
| Net Income | (70.51M) | (112.33M) | (141.43M) | (157.86M) | (258.8M) |
| Net Margin | -1516.0% | -4765.6% | -2054.8% | -2248.8% | -17253.3% |
| EPS (Basic) | (1.64) | (2.40) | (2.92) | (2.45) | (3.90) |
| EPS (Diluted) | (1.64) | (2.40) | (2.92) | (2.45) | (3.90) |
| Weighted Avg Shares | 42.87M | 46.89M | 48.45M | 64.4M | 66.5M |
| Weighted Avg Shares (Diluted) | 42.87M | 46.89M | 48.45M | 64.4M | 66.5M |
Celldex Therapeutics, Inc.
NASDAQ:CLDX
Intrinsic Alpha fair value
Locked
Current Price
$27.55
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.